# US Influenza Diagnostics Market > US Influenza Diagnostics Market Research Report: Size, Share, Trend Analysis By Types (PCR Tests, Antigen Tests, Serology Tests, Viral Culture, Rapid Diagnostic Tests), By Product (Reagents, Kits, Instruments, Consumables), By End-user (Hospitals, Clinics, Laboratories, Home Care), and By Technique (Molecular Diagnostics, Immunodiagnostics, Cell Culture) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.37% - **2024:** $ 2,269.68 Million - **2025:** $ 2,459.65 Million - **2035:** $ 5,491.97 Million - **Key Players:** Abbott (US), Roche (CH), Thermo Fisher Scientific (US), BD (US), Siemens Healthineers (DE), Cepheid (US), Hologic (US), BioMérieux (FR), QuidelOrtho (US) **Report ID:** MRFR/MED/55278-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-influenza-diagnostics-market-57044 --- ## Market Summary ## **US Influenza Diagnostics Market Overview** As per MRFR analysis, the US Influenza Diagnostics Market Size was estimated at 1.68 (USD Billion) in 2023. The US Influenza Diagnostics Market is expected to grow from 1.75 (USD Billion) in 2024 to 2.93 (USD Billion) by 2035. The US Influenza Diagnostics Market CAGR (growth rate) is expected to be around 4.791% during the forecast period (2025 - 2035). **Key US Influenza Diagnostics Market Trends Highlighted** Growing awareness of influenza's effects on public health is driving notable trends in the US influenza diagnostics market. The need for quicker and more precise diagnostic testing has increased as a result of an increase in seasonal flu outbreaks. Effective public health initiatives that highlight the significance of early influenza detection and treatment are also driving this need. Technological developments, such as the creation of point-of-care and rapid diagnostic tests, are improving the capacity to identify influenza rapidly, which is crucial during peak seasons when prompt action can drastically slow the spread of the illness. The use of machine learning and artificial intelligence in diagnostics is capturing market opportunities in the United States. In clinical contexts, these technologies can enhance test accuracy and streamline the decision-making process. A wider population will have easier access to influenza diagnostics because to the possibility of remote testing choices brought about by the growth of telemedicine. Effective testing and treatment are also made possible by laws that enable greater access to healthcare services. Influenza diagnostics are increasingly being customized to meet the needs of individual patients as part of a noticeable trend in personalized medicine in recent years. This change is a reflection of the US healthcare system's growing acceptance of precision health practices. Furthermore, current studies on combination testing and quadrivalent vaccines highlight the value of diagnostics in influenza management, which is consistent with CDC guidelines for all-encompassing flu prevention measures. All things considered, the US influenza diagnostics market is adjusting to the difficulties presented by influenza epidemics while also utilizing technological breakthroughs and legislative modifications to improve diagnostic capabilities. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review **US Influenza Diagnostics Market Drivers** **Increasing Incidence of Influenza in the US** The US Influenza Diagnostics Market is seeing growth due to the rising incidence of influenza cases. According to the Centers for Disease Control and Prevention (CDC), the United States experiences approximately 9 to 45 million cases of influenza annually, contributing to between 12,000 to 61,000 deaths each year. This surge in infection rates necessitates improved diagnostic tools, leading to increased demand for rapid and accurate influenza testing. Organizations such as Abbott and Roche Diagnostics are intensifying their investments in Research and Development for novel diagnostic products aimed at addressing this significant public health concern. Enhanced flu detection capabilities are essential for timely treatment and are expected to drive the growth of the US Influenza Diagnostics Market further, as healthcare providers strive to enhance patient outcomes and minimize complications associated with the disease. **Advancements in Diagnostic Technology** Technological advancements in diagnostic equipment are propelling growth in the US Influenza Diagnostics Market. The development of rapid molecular diagnostic tests has considerably improved the speed and accuracy of influenza detection. For instance, the FDA has approved newer tests that provide results in less than an hour. The advancement in multiplex testing, which can detect multiple influenza strains simultaneously, is also gaining traction. Companies like Cepheid and Quidel Corporation are at the forefront of these technological innovations. As a result, the availability of advanced diagnostic options is expected to enhance diagnostic capabilities across various healthcare settings in the US, ultimately expanding the market. **Government Initiatives and Funding** Government initiatives to combat influenza outbreaks are a critical driver for the US Influenza Diagnostics Market. The national strategy involves increased funding for influenza surveillance and prevention through initiatives led by the CDC and the Department of Health and Human Services (HHS). In recent years, the US government has emphasized improving public health responses to viral infections, including providing financial support for Research and Development of better diagnostic tools. For instance, in response to the COVID-19 pandemic, there was a marked increase in funding for respiratory disease diagnostics, which is likely to benefit the influenza diagnostics segment as well. Such governmental actions promote innovation and support for companies engaged in flu diagnostics, directly contributing to market growth. **US Influenza Diagnostics Market Segment Insights** **Influenza Diagnostics Market Type Insights** The US Influenza Diagnostics Market is characterized by a diverse range of testing types that cater to various needs within the healthcare industry. Among these, Polymerase Chain Reaction (PCR) Tests are renowned for their accuracy and rapid turnaround time, making them a preferred choice in clinical settings. These tests significantly enhance patient management and surveillance, as they can detect even minute amounts of viral RNA. Antigen Tests, on the other hand, are valued for their speed and simplicity, providing results in a matter of minutes; this makes them particularly effective in point-of-care settings and during outbreaks when quick decision-making is vital. Furthermore, Serology Tests play a crucial role in understanding population immunity and prior exposure to influenza viruses, which is essential for public health strategies aimed at preventing future outbreaks. Viral Culture remains an important method despite being less common due to its time-intensive process, as it allows for the isolation and identification of the influenza virus, contributing to effective vaccine development and surveillance. Rapid Diagnostic Tests are also significant as they offer convenience and rapid results, facilitating timely treatment decisions, and are often utilized in emergency departments. The combination of these various types creates a comprehensive framework for influenza diagnostics, driving innovations in methodologies and technology, and supporting overall market growth. Each of these testing types not only enhances the capabilities of healthcare providers but also addresses specific diagnostic needs, reflecting the trends towards precision medicine and personalized healthcare in the US. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review **Influenza Diagnostics Market Product Insights** The US Influenza Diagnostics Market is a rapidly evolving landscape with diverse product offerings that cater to the needs of healthcare professionals and patients. Within this segment, reagents play a critical role, as they are essential for various diagnostic tests, facilitating accurate and timely detection of influenza viruses. Meanwhile, kits, which combine reagents and other necessary components, are highly sought after due to their convenience and efficiency, making them a preferred choice in both clinical and home testing settings. Instruments designed for influenza diagnostics also contribute significantly to this market, providing advanced functionalities and improved testing accuracy, which are vital in laboratory environments. Furthermore, consumables, such as swabs and test tubes, offer the necessary accessories for sample collection and testing processes, ensuring that the workflow in diagnostic labs remains seamless. As public health initiatives and increased awareness of influenza prevention continue to rise in the US, the demand for these products is expected to grow, supported by ongoing innovations and technology advancements in the healthcare sector. This will create abundant opportunities for manufacturers and stakeholders within the US Influenza Diagnostics Market. **Influenza Diagnostics Market End-user Insights** The US Influenza Diagnostics Market showcases significant growth potential within its End-user segment, which includes Hospitals, Clinics, Laboratories, and Home Care. Hospitals dominate this segment, providing comprehensive diagnostic tools and treatment options, ensuring prompt patient care during influenza outbreaks. Clinics are also essential, often serving as the first point of contact for patients, driving demand for efficient testing methods to facilitate quicker diagnoses and mitigate the spread of the virus. Laboratories play a critical role in the accuracy and reliability of influenza testing, employing advanced technologies to conduct a range of tests, thus reinforcing their importance within the market. Home Care has emerged as a growing segment, driven by the convenience and accessibility it offers patients, especially amidst rising healthcare costs and a shift towards more personalized care solutions. Overall, the US Influenza Diagnostics Market segmentation reflects a varied landscape, with each segment contributing uniquely to the goal of effective influenza management. The increasing focus on early diagnosis and treatment is a key driver, as healthcare providers strive to enhance patient outcomes and reduce healthcare burdens associated with influenza outbreaks. **Influenza Diagnostics Market Technique Insights** The 'US Influenza Diagnostics Market' is a critical area of focus given the growing need for efficient and accurate influenza detection methods. The Technique segment plays a vital role within this market, encompassing various methodologies, including Molecular Diagnostics, Immunodiagnostics, and Cell Culture. Molecular Diagnostics utilizes nucleic acid amplification techniques, which enhance the speed and sensitivity of influenza detection, thus making it a preferred option in clinical settings. Immunodiagnostics rely on antigen detection through antibody assays, offering rapid results that are fundamental during flu outbreaks, particularly in hospital emergency departments. On the other hand, Cell Culture techniques, while more traditional, remain important for their ability to not only detect but also characterize the virus, contributing invaluable data for public health response strategies. With the increasing incidence of influenza and the emphasis on effective disease management and control, the Technique segment is projected to be instrumental in enhancing influenza outbreak preparedness and response across the United States. Continuous advancements and innovations in these diagnostic techniques are anticipated to drive market growth and improve patient outcomes by ensuring timely and accurate influenza diagnosis. **US Influenza Diagnostics Market Key Players and Competitive Insights** The US Influenza Diagnostics Market has evolved considerably, driven by an increasing demand for rapid and accurate influenza testing methods. This market is characterized by a mix of well-established firms and emerging players that are all vying for market share through innovation and improved product offerings. With an uptick in influenza cases, especially during the flu season, the emphasis on timely diagnostics has heightened, prompting companies to enhance their technology and methodologies. The industry's competitive landscape is shaped by factors such as advancements in molecular diagnostics, point-of-care testing capabilities, and strategic partnerships focused on research and development. Manufacturers are also facing pressure to comply with rigorous regulatory standards while striving to provide accurate and quicker diagnostic solutions to healthcare providers across the United States. Quidel Corporation has established a significant footprint in the US Influenza Diagnostics Market, thanks to its innovative product line that includes rapid influenza tests capable of delivering results in a matter of minutes. The company's strength lies in its commitment to enhancing diagnostic capabilities, facilitating effective disease management in clinical settings. Quidel Corporation has successfully positioned itself as a trusted provider by developing tests that not only meet the necessary regulatory requirements but also address the evolving needs of healthcare professionals. This reputation for reliability is further supported by solid partnerships with healthcare facilities, which enhances their product accessibility and distribution. The company's focus on R&D ensures a continuous stream of improved diagnostics, allowing it to maintain its competitive edge in the market. Siemens Healthineers holds a prominent position in the US Influenza Diagnostics Market, offering a range of products aimed at improving diagnostic acumen in clinical laboratories. Among its key offerings are advanced molecular diagnostic tests that help clinicians make informed decisions swiftly. The company benefits from a robust market presence bolstered by a strong portfolio that includes integrated laboratory solutions that streamline the testing process. Siemens Healthineers has made strategic investments in technology, particularly in point-of-care testing, enhancing its ability to meet the growing demand for rapid testing solutions. Mergers and acquisitions reinforce its growth strategy, as the company consistently seeks to expand its capabilities and market reach within the US. The synergy from these acquisitions allows Siemens Healthineers to innovate further, providing enhanced diagnostic tools that contribute positively to healthcare outcomes. **Key Companies in the US Influenza Diagnostics Market Include** - Quidel Corporation - Siemens Healthineers - Roche Diagnostics - Hepatitis Diagnostics Lab - Diagnostics For All - GenMark Diagnostics - Thermo Fisher Scientific - HoffmannLa Roche Ltd - BD - bioMerieux - Hologic - Epivax - Abbott Laboratories - Cepheid **US Influenza Diagnostics Market Developments** Recent developments in the US Influenza Diagnostics Market show an increasing focus on rapid testing technologies amid rising concerns over respiratory illnesses. Companies like Quidel Corporation and Abbott Laboratories are launching innovative products aimed at enhancing diagnostic accuracy and speed. In August 2023, Siemens Healthineers announced an expansion of its portfolio to include multiplex testing solutions that can detect various respiratory pathogens, including influenza. Furthermore, in September 2023, Roche Diagnostics introduced an upgraded version of its influenza test, which boasts improved sensitivity and specificity. Currently, GenMark Diagnostics and Hologic are also making notable strides with their automated testing systems, which are streamlining workflows in healthcare settings across the country. In the realm of mergers and acquisitions, F. Hoffmann-La Roche Ltd announced plans to acquire a small innovative diagnostics firm in July 2023, indicating an ongoing trend of consolidation in the sector. The overall growth in the market valuation of these companies is expected to enhance competition and drive advancements in diagnostic technologies, thereby significantly impacting patient care and public health responses in the US. The increased demand for influenza testing amidst broader public health efforts has positioned the sector for growth as it adapts to emerging healthcare challenges. **Influenza Diagnostics Market Segmentation Insights** - **Influenza Diagnostics Market Type Outlook** - PCR Tests - Antigen Tests - Serology Tests - Viral Culture - Rapid Diagnostic Tests - **Influenza Diagnostics Market Product Outlook** - Reagents - Kits - Instruments - Consumables - **Influenza Diagnostics Market End-user Outlook** - Hospitals - Clinics - Laboratories - Home Care - **Influenza Diagnostics Market Technique Outlook** - Molecular Diagnostics - Immunodiagnostics - Cell Culture ## Market Drivers ### Increased Healthcare Expenditure Rising healthcare expenditure in the US is a significant driver for the influenza diagnostics market. As healthcare budgets expand, there is a greater emphasis on preventive care and early diagnosis, which includes investments in diagnostic technologies. The US healthcare spending is projected to reach approximately $6 trillion by 2027, indicating a robust market for diagnostic solutions. This increase in funding allows healthcare facilities to acquire advanced diagnostic equipment and technologies, thereby improving the accuracy and speed of influenza detection. Furthermore, as healthcare providers seek to enhance patient care and reduce hospitalizations, the demand for effective influenza diagnostics is likely to rise, fostering market growth. ### Rising Incidence of Influenza Cases The increasing incidence of influenza cases in the US is a primary driver for the influenza diagnostics market. According to the Centers for Disease Control and Prevention (CDC), seasonal influenza affects millions of individuals annually, leading to significant healthcare costs. In the 2021-2022 season, there were approximately 9 million to 35 million cases reported, highlighting the ongoing need for effective diagnostic tools. This trend suggests that healthcare providers are likely to invest more in diagnostic solutions to manage and control outbreaks. As the population ages and the prevalence of chronic diseases rises, the demand for accurate and timely influenza diagnostics is expected to grow, thereby propelling the market forward. ### Emergence of Novel Influenza Strains The emergence of novel influenza strains poses a continuous challenge to public health. This challenge drives the influenza diagnostics market.. As new strains develop, the need for updated and effective diagnostic tools becomes paramount. The CDC monitors these strains closely, and the identification of new variants can lead to increased testing and surveillance efforts. This dynamic environment necessitates the development of advanced diagnostic technologies capable of detecting a wide range of influenza viruses. The market is likely to respond to this need by innovating and enhancing existing diagnostic solutions, ensuring that healthcare providers are equipped to address the challenges posed by evolving influenza strains. ### Advancements in Point-of-Care Testing The influenza diagnostics market is experiencing a surge in demand for point-of-care (POC) testing solutions. These advancements allow for rapid and accurate diagnosis of influenza at the site of patient care, which is crucial for timely treatment. The convenience of POC testing is particularly appealing in emergency departments and outpatient settings, where quick decision-making is essential. The market for POC testing is projected to grow significantly, with estimates suggesting a CAGR of over 10% through 2025. This growth is driven by the need for immediate results, which can lead to better patient outcomes and reduced transmission rates. Consequently, the development of innovative POC diagnostic tools is likely to enhance the overall landscape of the influenza diagnostics market. ### Growing Awareness of Influenza Vaccination The growing awareness of the importance of influenza vaccination is influencing the influenza diagnostics market. Public health campaigns and educational initiatives have led to increased vaccination rates, which in turn necessitate effective diagnostic tools to monitor and manage influenza outbreaks. As vaccination efforts expand, healthcare providers require reliable diagnostics to differentiate between vaccinated and unvaccinated individuals, ensuring appropriate treatment protocols. This heightened awareness is likely to drive demand for diagnostic solutions that can provide accurate results in a timely manner. Consequently, the influenza diagnostics market may see a positive impact as healthcare systems adapt to the evolving landscape of influenza management. ## Future Outlook The [Influenza Diagnostics Market](https://www.marketresearchfuture.com/reports/influenza-diagnostics-market-3142) is projected to grow at 8.37% CAGR from 2025 to 2035, driven by technological advancements, increased awareness, and rising healthcare expenditures. **New opportunities:** - Development of rapid point-of-care testing devices Integration of AI for predictive analytics in diagnostics Expansion of telehealth services for remote testing solutions By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs. ## Segment Insights ### By Type: PCR Tests (Largest) vs. Antigen Tests (Fastest-Growing) The US influenza diagnostics market showcases a diverse array of test types, with PCR tests holding the largest market share. Antigen tests have rapidly gained traction, appealing to healthcare providers due to their quick turnaround times and ease of use. Together, these two segments comprise the majority of diagnostic testing options available, reflecting differing preferences in clinical settings and patient needs. As the market evolves, antigen tests are projected to experience significant growth, driven by increasing investments in point-of-care diagnostics and rising demand for rapid testing solutions. PCR tests, while remaining dominant, may see a slight decline in growth as technological advancements in antigen tests and rapid diagnostic tests streamline influenza detection. This changing landscape is indicative of ongoing innovations and user preferences in influenza diagnostics. PCR Tests (Dominant) vs. Antigen Tests (Emerging) PCR tests are recognized for their high sensitivity and specificity, making them the gold standard in influenza diagnostics. They are widely used in clinical laboratories and hospitals due to their accuracy in detecting viral RNA. On the other hand, antigen tests are emerging as a popular alternative, particularly in outpatient settings and during public health crises, due to their rapid results and ease of administration. While PCR tests facilitate detailed analysis for confirmed cases, antigen tests provide immediate results for clinical decision-making. This dynamic highlights the coexistence of these segment values, catering to different diagnostic needs within the healthcare system. ### By Product: Kits (Largest) vs. Reagents (Fastest-Growing) In the US influenza diagnostics market, the distribution of market share among different product segments is characterized by the dominance of kits, accounting for a significant portion of the overall sales. Reagents, while traditionally lower in share, are witnessing rapid growth due to increasing demand for accurate and timely diagnostics, showcasing a shift in preference among healthcare providers toward comprehensive testing solutions. The growth trends in this segment are driven by advancements in technology and an increasing emphasis on early diagnosis. The emergence of rapid test kits and more sophisticated reagents reflects both the urgency of effective influenza management and the desire for efficiency in the diagnostic process. Factors such as rising awareness of respiratory infections and the expansion of healthcare facilities are further propelling the demand for these products. Kits (Dominant) vs. Reagents (Emerging) Kits represent the dominant force in the US influenza diagnostics market, primarily due to their user-friendly nature and the ability to deliver quick results. These kits cater to both home and clinical settings, making them incredibly accessible and practical for widespread use. On the other hand, reagents are emerging as a crucial element in the diagnostic landscape, driven by their essential role in laboratory testing and the growing necessity for precise diagnostic tools. As innovation continues in reagent formulations, they are becoming more sensitive and specific, which is enhancing their uptake in various diagnostic modalities. This contrast highlights a sector of stability in kits and a rapidly evolving landscape for reagents. ### By End User: Hospitals (Largest) vs. Home Care (Fastest-Growing) In the US influenza diagnostics market, the market share is primarily dominated by hospitals, which play a critical role in disease diagnosis and patient management. Hospitals are equipped with advanced diagnostic technologies and have a larger patient base, contributing significantly to their market share. Clinics and laboratories also hold substantial shares, but their footprint is comparatively smaller than that of hospitals. Home care, although currently smaller in terms of market share, is rapidly gaining traction, driven by consumer preferences for convenience and cost-effectiveness. The growth trends in this segment indicate a shift towards outpatient and home care solutions, particularly in the aftermath of the pandemic. Factors such as increased awareness about influenza and the convenience offered by home testing kits are driving the rise of home care services. Moreover, hospitals are continually innovating their diagnostic approaches to enhance patient outcomes, ensuring they retain their dominant market position while meeting the growing demands in this shifting landscape. Hospitals (Dominant) vs. Home Care (Emerging) Hospitals serve as the dominant force in the US influenza diagnostics market. They are equipped with state-of-the-art facilities and a wide array of diagnostic tools, allowing for comprehensive testing and rapid results. Their focus on patient care and adherence to strict clinical guidelines enhances their position in the market. Home care, on the other hand, is an emerging segment that leverages technological innovations for at-home testing. This shift is appealing to consumers seeking convenience and reduced hospital visits. As the market evolves, both segments will continue to adapt, with hospitals likely enhancing their capabilities and home care companies investing in user-friendly diagnostic solutions. ### By Technique: Molecular Diagnostics (Largest) vs. Immunodiagnostics (Fastest-Growing) In the US influenza diagnostics market, the segment values show a clear distribution where Molecular Diagnostics holds the largest share. This technique utilizes advanced technologies to detect the genetic material of the virus, allowing for quicker and more accurate diagnoses. On the other hand, Immunodiagnostics, which focuses on detecting antibodies or antigens, is gaining traction and is poised to become a significant player in the market as healthcare providers seek cost-effective and rapid testing solutions. Growth trends in this segment indicate a robust increase in demand driven by factors such as the rise in influenza outbreaks and the increasing awareness of rapid diagnostic solutions. Technology advancements that enhance the accuracy and speed of testing are further propelling this sector, making Immunodiagnostics one of the fastest-growing segments. Furthermore, the ongoing push towards personalized healthcare is encouraging the development of tailored solutions in both Molecular and Immunodiagnostic methods. Molecular Diagnostics (Dominant) vs. Immunodiagnostics (Emerging) Molecular Diagnostics is characterized by its precise detection of the influenza virus's genetic sequences using techniques like PCR, providing high sensitivity and specificity. Its dominant position in the US influenza diagnostics market is attributed to its ability to deliver quick results, which is critical during influenza seasons. In contrast, Immunodiagnostics, while newer in terms of technology, is an emerging contender. It focuses on serological testing that identifies the immune response to the virus, often being more cost-effective and quicker. As healthcare providers emphasize the need for rapid testing and outbreak management, Immunodiagnostics is expected to see significant growth, driven by its accessibility and the efficiency of testing processes. ### Influenza Diagnostics Market Technique Insights Influenza Diagnostics Market Technique Insights The 'US Influenza Diagnostics Market' is a critical area of focus given the growing need for efficient and accurate influenza detection methods. The Technique segment plays a vital role within this market, encompassing various methodologies, including Molecular Diagnostics, Immunodiagnostics, and Cell Culture. Molecular Diagnostics utilizes nucleic acid amplification techniques, which enhance the speed and sensitivity of influenza detection, thus making it a preferred option in clinical settings. Immunodiagnostics rely on antigen detection through antibody assays, offering rapid results that are fundamental during flu outbreaks, particularly in hospital emergency departments. ## Competitive Benchmarking The influenza diagnostics market is characterized by a dynamic competitive landscape, driven by the increasing prevalence of influenza and the demand for rapid and accurate diagnostic solutions. Key players such as Abbott (US), Roche (CH), and Thermo Fisher Scientific (US) are strategically positioned to leverage innovation and technological advancements. Abbott (US) focuses on enhancing its product portfolio through continuous research and development, while Roche (CH) emphasizes strategic partnerships to expand its diagnostic capabilities. Thermo Fisher Scientific (US) is actively pursuing mergers and acquisitions to bolster its market presence, indicating a trend towards consolidation in the sector. Collectively, these strategies contribute to a competitive environment that is increasingly focused on innovation and technological integration.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The market structure appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for diverse offerings, yet the collective strength of major companies shapes the competitive dynamics, fostering an environment where innovation is paramount. In October Abbott (US) announced the launch of a new rapid influenza diagnostic test that utilizes advanced molecular technology, significantly reducing the time required for results. This strategic move not only enhances Abbott's product offerings but also positions the company to capture a larger share of the growing demand for rapid testing solutions. The introduction of this test is likely to strengthen Abbott's competitive edge in a market that increasingly values speed and accuracy. In September Roche (CH) entered into a collaboration with a leading technology firm to integrate artificial intelligence into its diagnostic platforms. This partnership aims to enhance the accuracy of influenza diagnostics and streamline the testing process. By leveraging AI, Roche (CH) is poised to improve patient outcomes and operational efficiency, reflecting a broader trend towards digital transformation in the diagnostics sector. In August Thermo Fisher Scientific (US) completed the acquisition of a smaller diagnostics company specializing in point-of-care testing. This acquisition is expected to expand Thermo Fisher's capabilities in the influenza diagnostics market, allowing for a more comprehensive product range. The strategic importance of this move lies in Thermo Fisher's ability to integrate innovative technologies and enhance its market position through a diversified portfolio. As of November current competitive trends in the influenza diagnostics market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of agility and responsiveness in meeting the evolving needs of healthcare providers and patients. ## Recent News & Developments Recent developments in the US Influenza Diagnostics Market show an increasing focus on rapid testing technologies amid rising concerns over respiratory illnesses. Companies like Quidel Corporation and Abbott Laboratories are launching innovative products aimed at enhancing diagnostic accuracy and speed. In August 2023, Siemens Healthineers announced an expansion of its portfolio to include multiplex testing solutions that can detect various respiratory pathogens, including influenza. Furthermore, in September 2023, Roche Diagnostics introduced an upgraded version of its influenza test, which boasts improved sensitivity and specificity. Currently, GenMark Diagnostics and Hologic are also making notable strides with their automated testing systems, which are streamlining workflows in healthcare settings across the country. In the realm of mergers and acquisitions, F. Hoffmann-La Roche Ltd announced plans to acquire a small innovative diagnostics firm in July 2023, indicating an ongoing trend of consolidation in the sector. The overall growth in the market valuation of these companies is expected to enhance competition and drive advancements in diagnostic technologies, thereby significantly impacting patient care and public health responses in the US. The increased demand for influenza testing amidst broader public health efforts has positioned the sector for growth as it adapts to emerging healthcare challenges. ## Report Scope | MARKET SIZE 2024 | 2269.68(USD Million) | | --- | --- | | MARKET SIZE 2025 | 2459.65(USD Million) | | MARKET SIZE 2035 | 5491.97(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.37% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott (US), Roche (CH), Thermo Fisher Scientific (US), BD (US), Siemens Healthineers (DE), Cepheid (US), Hologic (US), BioMérieux (FR), QuidelOrtho (US) | | Segments Covered | Type, Product, End User, Technique | | Key Market Opportunities | Integration of rapid testing technologies enhances early detection capabilities in the influenza diagnostics market. | | Key Market Dynamics | Technological advancements drive rapid innovation in influenza diagnostics, enhancing accuracy and speed of detection. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US influenza diagnostics market in 2024?** A: The overall market valuation was $2269.68 Million in 2024. **Q: What is the projected market valuation for the US influenza diagnostics market by 2035?** A: The projected market valuation for 2035 is $5491.97 Million. **Q: What is the expected CAGR for the US influenza diagnostics market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during 2025 - 2035 is 8.37%. **Q: Which segment had the highest valuation in the US influenza diagnostics market in 2024?** A: In 2024, the Antigen Tests segment had the highest valuation at $600.0 Million. **Q: What are the projected valuations for PCR Tests in the US influenza diagnostics market by 2035?** A: The projected valuation for PCR Tests by 2035 is $1200.0 Million. **Q: Which key players are leading the US influenza diagnostics market?** A: Key players include Abbott, Roche, Thermo Fisher Scientific, BD, Siemens Healthineers, Cepheid, Hologic, BioMérieux, and QuidelOrtho. **Q: What is the valuation range for Kits in the US influenza diagnostics market?** A: The valuation range for Kits is projected between $800.0 Million and $2000.0 Million. **Q: How much is the Home Care segment expected to grow by 2035?** A: The Home Care segment is expected to grow to $1491.97 Million by 2035. **Q: What is the valuation for Molecular Diagnostics in the US influenza diagnostics market in 2024?** A: The valuation for Molecular Diagnostics in 2024 was $908.68 Million. **Q: What is the expected valuation for Consumables in the US influenza diagnostics market by 2035?** A: The expected valuation for Consumables by 2035 is projected to be $991.97 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-influenza-diagnostics-market-57044*